Director dealings: AstraZeneca director makes share purchase
19th Feb 2020 16:50
(Sharecast News) - AstraZeneca revealed on Wednesday that non-executive director Michel Demare had acquired 700 ordinary shares in the FTSE 100-listed pharmaceutical giant.
Read moreMonday broker round-up
17th Feb 2020 13:05
(Sharecast News) - Hikma Pharmatheuticals: Citigroup downgrades to neutral with a target price of 1,980p.
Read moreLondon midday: Stocks steady as some analysts sound hopeful note on coronavirus
14th Feb 2020 11:27
(Sharecast News) - Stocks have recovered from an early dip after the World Health Organisation said overnight that the spike in coronavirus cases in China on Thursday are not new infections.
Read moreLondon open: Stocks little changed as traders reassess coronavirus risks
14th Feb 2020 08:00
(Sharecast News) - Stocks slipped in early trading as traders grappled with the difficulty of pinpointing how far along China really was in controlling the outbreak of a new coronavirus in the country.
Read moreAstraZeneca profit falls as costs and writedowns increase
14th Feb 2020 07:03
(Sharecast News) - AstraZeneca's annual profit fell 14% as rising costs and higher asset writedowns offset sales increases at the pharmaceutical company.
Read moreAstra reports positive results from stroke, gastric cancer trials
27th Jan 2020 09:24
(Sharecast News) - AstraZeneca said high-level results from from a phase three trial of its Brilinta drug used in conjunction with aspirin produced a "statistically significant and clinically meaningful" fall in the risk of the primary composite endpoint of stroke and death, compared with aspirin alone.
Read moreAstraZeneca sells hypertension drug rights; Ends Allergan deal
27th Jan 2020 07:53
(Sharecast News) - AstraZeneca said it had agreed to sell the global commercial rights to a range of hypertension treatments to Atnahs Pharma for up to $390m.
Read moreWednesday broker round-up
22nd Jan 2020 12:52
(Sharecast News) - Experian: Morgan Stanley upgrades to overweight with a target price of 2,950p.
Read moreAstraZeneca clears regulatory hurdles with 'Imfinzi' and 'Lynparza'
20th Jan 2020 07:19
(Sharecast News) - AstraZeneca announced on Monday that its 'Imfinzi' (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted orphan drug designation by the Food and Drug Administration (FDA) in the United States, for the treatment of hepatocellular carcinoma (HCC), which is the most common type of liver cancer.
Read moreThursday broker round-up
16th Jan 2020 12:58
(Sharecast News) - Diageo: Jefferies downgrades to hold with a target price of 3,600p
Read moreAstraZeneca upbeat on 'Lynparza' decision, closes 'Epanova' trial
13th Jan 2020 07:32
(Sharecast News) - AstraZeneca and its partner MSD announced that a supplemental New Drug Application for 'Lynparza' - olaparib - in combination with bevacizumab, has been accepted and granted priority review status in the United States for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to first-line platinum-based chemotherapy with bevacizumab.
Read moreAstraZeneca clears regulatory hurdles in US and China
6th Jan 2020 08:22
(Sharecast News) - AstraZeneca cleared two regulatory approvals on Monday - one for 'Farxiga' in the United States, and one for 'Lokelma' in China.
Read moreAstraZeneca gets US approval for 'Lynparza' in pancreatic cancer
30th Dec 2019 08:15
(Sharecast News) - AstraZeneca announced on Monday, alongside its partner MSD, that 'Lynparza', or olaparib, has been approved in the United States for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma, or pancreatic cancer, whose disease had not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.
Read moreAstraZeneca upbeat on approvals in China and the US
23rd Dec 2019 07:40
(Sharecast News) - AstraZeneca announced on Monday that budesonide/glycopyrronium/formoterol fumarate has been approved in China for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
Read moreFriday broker round-up
20th Dec 2019 12:28
(Sharecast News) - Segro: HSBC downgrades to hold with a target price of 869p.
Read more